BONEX Stock Overview
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bonesupport Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 335.20 |
| 52 Week High | SEK 367.60 |
| 52 Week Low | SEK 159.60 |
| Beta | 0.97 |
| 11 Month Change | -0.59% |
| 3 Month Change | 22.43% |
| 1 Year Change | 104.76% |
| 33 Year Change | 791.49% |
| 5 Year Change | 900.60% |
| Change since IPO | 947.50% |
Recent News & Updates
Shareholder Returns
| BONEX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -5.3% | -5.6% | -3.6% |
| 1Y | 104.8% | 17.3% | 12.3% |
Return vs Industry: BONEX exceeded the Swedish Biotechs industry which returned 17.3% over the past year.
Return vs Market: BONEX exceeded the Swedish Market which returned 12.3% over the past year.
Price Volatility
| BONEX volatility | |
|---|---|
| BONEX Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: BONEX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: BONEX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 131 | Emil Billbäck | www.bonesupport.com |
Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management.
Bonesupport Holding AB (publ) Fundamentals Summary
| BONEX fundamental statistics | |
|---|---|
| Market cap | SEK 22.85b |
| Earnings (TTM) | SEK 90.58m |
| Revenue (TTM) | SEK 814.46m |
243.5x
P/E Ratio27.1x
P/S RatioIs BONEX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BONEX income statement (TTM) | |
|---|---|
| Revenue | SEK 814.46m |
| Cost of Revenue | SEK 61.64m |
| Gross Profit | SEK 752.82m |
| Other Expenses | SEK 662.24m |
| Earnings | SEK 90.58m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 1.38 |
| Gross Margin | 92.43% |
| Net Profit Margin | 11.12% |
| Debt/Equity Ratio | 0% |
How did BONEX perform over the long term?
See historical performance and comparison